Welcome to our dedicated page for Evotec SEC filings (Ticker: EVO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles Evotec SE (EVO) filings with the U.S. Securities and Exchange Commission, giving investors structured access to the company’s regulatory disclosures. As a foreign private issuer, Evotec files its annual report on Form 20-F and submits interim information and material updates on Form 6-K.
Recent Form 6-K submissions referenced in the company’s disclosures include reports on financial results for the first half and first nine months of 2025, adjustments to revenue guidance while confirming profit guidance, and details of a share repurchase program. Other 6-Ks transmit press releases on strategic transactions, such as the planned and then finalized agreements with Sandoz regarding the Just - Evotec Biologics Toulouse site and an indefinite license to Evotec’s continuous manufacturing platform technology.
Additional 6-K filings cover business updates on Evotec’s strategy for sustainable and profitable growth, including the renaming of its Shared R&D segment to Discovery & Preclinical Development, progress in collaborations with Bristol Myers Squibb and Bayer, and the evolution of Just - Evotec Biologics toward an asset-lighter, technology-centric model.
Through Stock Titan, users can review these SEC documents alongside AI-powered summaries that clarify key points from lengthy filings. This includes context on revenue mix, cost initiatives, strategic partnerships, and capital allocation measures such as buybacks. For deeper analysis, investors can focus on how Evotec describes its platform technologies, partnered R&D asset portfolio, and guidance for future periods within its official filings.
Evotec SE reported it has signed a final agreement with Sandoz. According to the company’s announcement, the transaction could result in payments potentially over US$ 650 m, plus royalties tied to a portfolio of up to 10 biosimilar molecules.
The update was furnished via a Form 6-K alongside a press release. The disclosure highlights the scale of the collaboration and the royalty-bearing structure on a multi-asset biosimilar portfolio, indicating a broad, long-term commercial framework with Sandoz.
Evotec SE filed a Form 6-K to furnish a press release covering its financial results and business updates for the first six months of 2025. The release, dated August 13, 2025 and attached as Exhibit 99.1, is titled “Evotec SE reports H1 2025 results: Strong progress on strategy execution.”
This filing mainly serves to formally provide that press release to investors and regulators and indicates that Evotec reports annually on Form 20-F.